systemic primary carnitine deficiency inborn error fatty acid transport caused defect transporter responsible moving carnitine across plasma membrane carnitine important amino acid fatty acid carnitine transported tissues fatty acid oxidation impaired leading variety symptoms chronic muscle weakness cardiomyopathy hypoglycemia liver dysfunction specific transporter involved spcd coded gene located chromosome spcd inherited autosomal recessive manner mutated alleles coming parents acute episodes due spcd often preceded metabolic stress extended fasting infections vomiting cardiomyopathy develop absence acute episode result death spcd leads increased carnitine excretion urine low levels plasma locations expanded newborn screening spcd identified treated shortly birth treatment high doses carnitine supplementation effective needs rigorously maintained life presentation patient spcd incredibly varied asymptomatic lethal cardiac early cases reported liver dysfunction muscular findings weakness underdevelopment hypoketotic hypoglycemia cardiomegaly cardiomyopathy marked carnitine deficiency plasma tissues combined increased excretion patients present clinically spcd fall two categories metabolic presentation hypoglycemia cardiac presentation characterized cardiomyopathy muscle weakness found either countries expanded newborn screening spcd identified shortly birth affected infants show low levels free carnitine acylcarnitine species tandem mass infants low free carnitine affected spcd may carnitine deficiency secondary another metabolic condition due maternal carnitine deficiency proper followup newborn screening results low free carnitine includes studies mother determine whether carnitine deficiency due spcd secondary metabolic disease maternal cases spcd identified higher expected rate often women mothers also identified newborn screening cardiomyopathy previously identification treatment asymptomatic individuals still developing clear whether require levels intervention patients identified spcd early life based clinical spcd autosomal recessive condition meaning mutated allele must inherited parent individual gene responsible carnitine transporter located regulated peroxisome proliferatoractivated receptor alpha transporter located apical membrane renal tubular cells plays role tubular defective unable recapture carnitine prior excretion urine leading characteristic biochemical findings massively increased urine carnitine levels significantly decreased plasma carnitine decreased levels plasma carnitine inhibit fatty acid oxidation times excessive energy demand carnitine needed transport long chain fatty acids mitochondria broken produce acetylcoa individuals spcd produce ketone bodies energy due interruption fatty acid although spcd autosomal recessive condition heterozygotes shown increased risk developing benign cardiomyopathy compared wild type first suspicion spcd patient nonspecific presentation extremely low plasma carnitine level combined increased concentration carnitine urine suspicion spcd often confirmed either molecular testing functional studies assessing uptake carnitine cultured identification patients presymptomatically via newborn screening allowed early intervention treatment treatment spcd involves high dose carnitine supplementation must continued individuals identified treated birth good outcomes including prevention mothers identified positive newborn screen otherwise asymptomatic typically offered carnitine supplementation well longterm outcomes asymptomatic adults spcd known discovery mothers undiagnosed cardiomyopathy spcd raised possibility identification treatment may prevent adultonset worldwide spcd common faroe islands least one every inhabitants faroes disorder according faroese ministry scientists believe around faroese population carriers variants cause people ill may lower amount carnitine blood noncarriers first faroese patient diagnosed spcd since several young people children faroese islands died cardiac arrest addition spcd newborn screening panels offered insight incidence disorder around world taiwan incidence spcd newborns estimated approximately maternal cases identified higher frequency approximately increased incidence spcd mothers compared newborns completely estimates spcd japan shown similar incidence carnitine deficiency extensively studied although commonly secondary finding metabolic first case spcd reported child fasting hypoketotic hypoglycemia resolved treatment carnitine supplementation later cases reported cardiomyopathy muscle weakness newborn screening expanded potential phenotypes associated spcd include otherwise asymptomatic httpsenwikipediaorgwikisystemicprimarycarnitinedeficiency